Cerebrolysin Protected Against Cell Death in Only 30% of Patients with a Rare Hereditary Brain Disease

The researchers collected peripheral blood lymphocytes from 15 CADASIL patients (ages 34–70). They cultured these cells in the lab and exposed them to 2-deoxy-D-ribose, a sugar that triggers oxidative stress and cell death. Cerebrolysin was then added to see if it could prevent the cells from dying. Cell death was measured using flow cytometry and fluorescence microscopy after 48 hours of culture.

CADASIL is a devastating hereditary condition that causes strokes and dementia, and there are currently no disease-modifying treatments. Understanding whether neuroprotective peptide drugs like cerebrolysin could help these patients is an important research question, even if this early in-vitro study found limited effectiveness.

Cerebrolysin has shown neuroprotective effects in stroke and dementia research, but this study suggests those benefits may not extend uniformly to genetic conditions like CADASIL. The variable response among patients highlights how genetic background can influence drug effectiveness and underscores the challenge of finding treatments for rare hereditary neurological diseases.

This was an in vitro study using blood cells in a lab dish, not brain tissue, so results may not reflect what happens in the brain. The sample size of 15 patients is very small. The study only measured one type of stress (oxidative) and one time point (48 hours). There was no explanation for why 30% of patients responded while 70% did not, beyond speculation about the Notch3 gene.